AUTHORS
Komal Mandleywala, Simona Ulrich2, Victoria Da Silva Diz3, Puneet Sharma4, Christopher Thai5, Oekyung Kim6, Maya Aleksandrova7, Yuan Yuan8, Loredana Cantoni9, Rodrigo Prieto-Bermejo10, Le Le11, Gwendolyn Chung12, Cristian Eggers13, Antonio Marino14, Tanaya Kulkarni15, Amartya Singh16, Fabio Steffen17, jean Pierre Bourquin, MD, PhD18, Dieter Luetjohann19, M. Elena Díaz-Rubio20, Michael Wierer21, Sebastian Leidel22, Xiaoyang Su23, Tracy Anthony24, Teresa Palomero25, Adolfo Ferrando, MD, PhD26, Eileen White27, Joshua D. Rabinowitz28, Raphael Johannes Morscher29, Daniel Herranz, PharmD, PhD30
AFFILIATIONS
1 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
2 University of Zurich, Zurich, Switzerland
3 Rutgers Cancer Institute, New Brunswick, United States
4 University of Zurich, Zurich, Switzerland
5 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
6 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
7 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
8 University of Zurich, Zurich, Switzerland
9 University of Zurich, Zurich, Switzerland
10 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
11 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
12 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
13 University of Bern, Bern, Switzerland
14 University of Copenhagen, Copenhagen, Denmark
15 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
16 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
17 University of Zurich, Zurich, Switzerland
18 University of Zurich, Zurich, Switzerland
19 University Hospital Bonn, Bonn, Germany
20 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
21 University of Copenhagen, Copenhagen, Denmark
22 University of Bern, Bern, Switzerland
23 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
24 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
25 Columbia University, New York, United States
26 Regeneron, Tarrytown, United States
27 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
28 Princeton University, Princeton, United States
29 University of Zurich, Zurich, Switzerland
30 Rutgers Cancer Institute, New Brunswick, New Jersey, United States
ABSTRACT
Abstract: T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy representing 10–15% of pediatric and 25% of adult ALL cases. Despite improvements in overall survival driven by intensive chemotherapy, approximately 20–50% of patients relapse and the prognosis of relapsed and refractory disease remains extremely poor. Even if cured, most T-ALL survivors are at risk for long-term side effects caused by either leukemia itself or by the intensive treatments, overall highlighting the need to discover safer and more effective therapeutic approaches. Notably, several drugs central to the current T-ALL treatment regimen, including L-asparaginase, methotrexate, 6-mercaptopurine or cytarabine, exert antileukemic effects by targeting specific metabolic pathways, highlighting the sensitivity and amenability of T-ALL to metabolic changes. Beyond such cell-intrinsic metabolic targets, dietary modulation of systemic metabolism has shown promising antitumor effects in preclinical models and is under clinical evaluation. However, most studies have examined single dietary interventions in non-orthotopic or immunocompetent systems, leaving the relative impact of distinct dietary perturbations on primary disease mostly unresolved.
To address this, we performed an in vivo screen of diets individually lacking each proteinogenic amino acid, leveraging a primary, orthotopic, and immunocompetent NOTCH1-driven T-ALL mouse model. Among all amino acids tested, histidine-deficient diets produced the strongest antileukemic effect with a 2-3-fold extension in survival and showcased an uniquely favorable tolerability profile compared to other antileukemic amino acid restrictions. Of note, the impact of dietary histidine in cancer progression is largely unknown, thus, we focused our subsequent efforts on dissecting the unique effects of dietary histidine in T-ALL progression.
Dietary histidine restriction produced antileukemic effects that were found to be dose-dependent and were recapitulated in human T-ALL and B-ALL PDXs (spanning distinct molecular subgroups and driver mutations) in immunodeficient mice, supporting that at least part of its therapeutic effects are leukemic cell-intrinsic. Additionally, short-term dietary histidine restriction for two weeks in healthy mice showed a drastic impairment in normal T-cell development, in line with the effects of most standard-of-care therapies against T-ALL, while sparing other peripheral blood cell populations, including neutrophils, red blood cells or platelets. The remarkable absence of neutropenia, anemia, and thrombocytopenia, which are dose-limiting toxicities of most cytotoxic leukemia therapies, supports further clinical evaluation of histidine-targeting strategies.
Mechanistically, Ribo-seq analyses showed histidine depletion triggers stalling-driven ribosome collisions at histidine codons, resulting in GCN2 kinase activation, alongside activation of PERK and ISR. Multi-omic integration across transcriptomic, ribosomal, and proteomic data, consistently identified cholesterol biosynthesis as the most strongly suppressed pathway by histidine restriction across all expression levels. Importantly, genetic GCN2 knockdown or pharmacological GCN2 inhibition in human T-ALL cells rescued both cholesterol biosynthesis and the antiproliferative effects of histidine restriction. Conversely, pharmacological GCN2 activation alone was sufficient to suppress cholesterol biosynthesis. Moreover, overexpression of SREBF2, the master regulator of cholesterol biosynthesis, rescued the antiproliferative effects, establishing the GCN2-SREBF2 axis as the central mechanism underlying histidine restriction. These findings unexpectedly coupled histidine availability to cholesterol metabolism through GCN2-dependent signaling.
Consistent with these results, the combination of histidine restriction with simvastatin treatment produced synergistic antileukemic effects in vivo. Most notably, dietary cholesterol supplementation rescued the antileukemic effects of histidine depletion both in human T-ALL cells in vitro and in mouse primary T-ALL in vivo, suggesting a histidine restriction-induced cholesterol auxotrophy in leukemic cells. Collectively, these findings uncover a previously unrecognized connection between histidine availability, translational control and cholesterol metabolism in T-ALL, defining a novel and therapeutically exploitable vulnerability.
DISCLOSURES
Komal Mandleywala: No relevant conflicts of interest to declare.